Trial Outcomes & Findings for Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease (NCT NCT00670709)

Results Overview

Absolute power in the delta frequency as measured by quantitative electroencephalography

Recruitment status

COMPLETED

Target enrollment

42 participants

Primary outcome timeframe

baseline- one time point

Results posted on

2023-11-09

Participant Flow

Recruitment began September 2006 and ended in February 2008. All recruitment took place at UCLA Neurology Clinic and the UCLA Semel Institute.

Participant milestones

Participant milestones
Measure	Huntington Disease Subjects with mild or moderate Huntington's Disease	Healthy Controls Healthy control subjects
Overall Study STARTED	27	15
Overall Study COMPLETED	27	15
Overall Study NOT COMPLETED	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Huntington Disease n=27 Participants Subjects with mild or moderate Huntington's Disease	Healthy Controls n=15 Participants Healthy control subjects	Total n=42 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants
Age, Categorical Between 18 and 65 years	27 Participants n=93 Participants	15 Participants n=4 Participants	42 Participants n=27 Participants
Age, Categorical >=65 years	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants
Age, Continuous	46.4 years STANDARD_DEVIATION 11.3 • n=93 Participants	47.3 years STANDARD_DEVIATION 9.7 • n=4 Participants	46.85 years STANDARD_DEVIATION 10.5 • n=27 Participants
Sex: Female, Male Female	11 Participants n=93 Participants	8 Participants n=4 Participants	19 Participants n=27 Participants
Sex: Female, Male Male	16 Participants n=93 Participants	7 Participants n=4 Participants	23 Participants n=27 Participants
Region of Enrollment United States	27 participants n=93 Participants	15 participants n=4 Participants	42 participants n=27 Participants

PRIMARY outcome

Timeframe: baseline- one time point

Absolute power in the delta frequency as measured by quantitative electroencephalography

Outcome measures

Outcome measures
Measure	Huntington Disease n=27 Participants Subjects with mild or moderate Huntington's Disease	Healthy Controls n=15 Participants Healthy control subjects
Quantitative Electroencephalography Absolute Delta Power.	43.45 microvolts squared Standard Deviation 10.83	10.11 microvolts squared Standard Deviation 3.01

PRIMARY outcome

Timeframe: baseline EEG

Absolute power in the alpha frequency as measured by quantitative electroencephalography

Outcome measures

Outcome measures
Measure	Huntington Disease n=27 Participants Subjects with mild or moderate Huntington's Disease	Healthy Controls n=15 Participants Healthy control subjects
Quantitative Electroencephalography Absolute Alpha Power.	56.09 microvolts squared Standard Deviation 62.61	18.12 microvolts squared Standard Deviation 15.04

Adverse Events

Huntington Disease

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Healthy Controls

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jennifer Villalobos

UCLA

Phone: 310-825-3351

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place